Update on Regulatory Status of Hypertension, Biomarkers and Arrhythmia Monitoring in Clinical Trials. Join us at FDA White Oak Campus to examine proarrhythmia, hypertension and biomarkers.

In Session 1, leading industry professionals will speak on panels discussing:

  • Regulations for ECG/QT
  • The double-negative conundrum
  • Alternative methods for assay sensitivity assessment in routine Phase 1 QT Studies
  • Covid-19 and prolonged QT

In Session 2, the following topics will be discussed:

  • Small increases in blood pressure and CV risk
  • Intermittent versus chronic use of hypertension drugs

In Session 3, the meeting faculty will dive into:

  • Biomarkers

In Session 4, the panelists will discuss hot topics in the field such as:

  • Biologics/cardiomyopathy and vaccine development
  • MACE
  • Gene therapies
  • Wearables

We will be joined by professionals from FDA Regulatory, Cardiac Safety Consultants, Ltd., Eli Lilly, Richmond Pharmacology, University of Connecticut, Stanford University, University of Pennsylvania, Cleveland Clinic, Clario, Mass General, DSI, Penn Medicine, and UCSF.

Our CEO Jorg Taubel will be presenting on the topic of alternative methods for assay sensitivity assessment in routine Phase 1 QT Studies, as well as taking part in a panel about Proarrhythmia.

Latest news

Richmond Pharmacology Appoints Patrick Ramiah as Director of Clinical Project Delivery & Operational Excellence

September 1, 2025
Richmond Pharmacology is delighted to announce the promotion of Patrick Ramiah to the role of Director of Clinical Project Delivery & Operational Excellence, effective from 1 September 2025.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event